Hypofractionated Radiation Therapy in the Definitive Management of Head and Neck Cancer. Semin Radiat Oncol 2025 Apr;35(2):190-196
Date
03/17/2025Pubmed ID
40090745DOI
10.1016/j.semradonc.2025.01.002Scopus ID
2-s2.0-86000790211 (requires institutional sign-in at Scopus site) 2 CitationsAbstract
The use of hypofractionated radiation therapy has increased among many cancers, although its use in head and neck cancers remains limited due to concerns regarding acute and late toxicities. Recent retrospective and prospective studies demonstrate the preliminary safety and efficacy of hypofractionation in the definitive, postoperative, and preoperative settings for head and neck treatment. This article seeks to comprehensively review the rationale and data for novel fractionation schemes in this disease site. We also provide practical clinical and dosimetric insights based on our institutional experiences with hypofractionation in head and neck cancers.
Author List
Moon DH, Awan MJAuthor
Musaddiq J. Awan MD Associate Professor in the Radiation Oncology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Head and Neck NeoplasmsHumans
